Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

• DOI: 10.2147/ijn.s332830
• Publication Date: 2021-10-15T20:32:27Z
• Authors: Xin Yang; Yifan Wang; Si Chen; Shuang Zhang; Chunying Cui
• Keywords: MTT assay; Human serum albumin

Breast cancer is the most prevalent among women. Doxorubicin (DOX) a common chemotherapeutic drug used to treat many different cancers. However, multidrug resistance limits treatment of breast cancer. MDR1 siRNA (siMDR1) combinatorial therapy has attracted significant attention as breakthrough for in tumors. naked easily degraded by enzymatic hydrolysis requiring an carrier its protection. Human serum albumin (HSA) was selected due excellent biocompatibility, non-toxicity, and non-immunogenicity. Cetuximab modify HSA nanoparticles order target tumor tissues.This study central composite design response surface methodology (CCD-RSM) investigate optimal formula NPs preparation. Cex-HSA/DOX/MDR1 (C-H/D/M) characterized dynamic light scattering transmission electron microscopy. The efficacy C-H/D/M growth inhibitory activity investigated vitro vivo using confocal imaging, MTT assay, MCF-7/ADR tumor-bearing mice model. RT-qPCR, ELISA analysis, flow cytometry were antitumor mechanisms C-H/D/M.The diameter PDI 173.57 ± 1.30 nm 0.027 0.004, respectively. promoted maintained sustained release uptake DOX significantly. After transfection, mRNA P-gp expression levels down-regulated 44.31 3.6% (P < 0.01) 38.08 2.4% cell line. fluorescent images treated BALB/c nude revealed that achieved targeted delivery siMDR1 into tissue. inhibition results demonstrated rate group 54.05% 1.25%. biosafety indicated did not induce damages main organs vivo.C-H/D/M can be ideal non-viral tumor-targeting vector overcome MDR enhance effect.